

ZISPER®IR

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for ZISPER®IR [Risperidone Tablets I.P.]

[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: Risperidone is a selective monoaminergic antagonist with unique properties. It has a high affinity for serotonergic 5-HT₂ and dopaminergic D₂ receptors. Risperidone binds also to alpha₁-adrenergic receptors, and, with lower affinity, to H₁-histaminergic and alpha₂-adrenergic receptors. Risperidone has no affinity for cholinergic receptors. Although risperidone is a potent D₂ antagonist, which is considered to improve the positive symptoms of schizophrenia, it causes less depression of motor activity and induction of catalepsy than classical antipsychotics. Balanced central serotonin and dopamine antagonism may reduce extrapyramidal side effect liability and extend the therapeutic activity to the negative and affective symptoms of schizophrenia.

INDICATIONS: It is indicated in the treatment of acute and chronic schizophrenic psychoses and other psychotic conditions in which positive symptoms and negative symptoms are prominent

DOSAGE AND ADMINISTRATION: Risperidone tablets may be given once daily or twice daily. Risperidone tablets are for oral use. Food does not affect the absorption of Risperidone tablets.

CONTRAINDICATION: Hypersensitivity to the active substance or to any of the excipients.

WARNINGS & PRECAUTIONS: Elderly patients with dementia, Cerebrovascular Adverse Events (CVAE), Orthostatic hypotension, Leukopenia, neutropenia, and agranulocytosis, Tardive dyskinesia/extrapyramidal symptoms (TD/EPS), Neuroleptic malignant syndrome (NMS), Parkinson's disease and dementia with Lewy bodies, Hyperglycaemia and diabetes mellitus, Weight gain, Hyperprolactinaemia, QT prolongation, Seizures, Priapism, Body temperature regulation, Antiemetic effect, Renal and hepatic impairment, Venous thromboembolism (VTE), Intraoperative Floppy Iris Syndrome, Paediatric population,

DRUG INTERACTIONS: Risperidone should be used with caution in combination with other centrally-acting substances notably including alcohol, opiates, antihistamines and benzodiazepines due to the increased risk of sedation. Risperidone may antagonise the effect of levodopa and other dopamine agonists. If this combination is deemed necessary, particularly in end-stage Parkinson's disease, the lowest effective dose of each treatment should be prescribed.

ADVERSE REACTIONS: Pneumonia, bronchitis, upper respiratory tract infection, sinusitis, urinary tract infection, ear infection, influenza, cystitis, eye infection, tonsillitis, onychocytosis, cellulitis, neutropenia, thrombocytopenia, eosinophil count, agranulocytosis, hypersensitivity, anaphylactic reaction, hyperprolactinaemia, inappropriate antidiuretic hormone secretion, glucose mania, confusional state, libido decreased, nervousness, nightmare, urine present tardive dyskinesia, cerebral ischaemia, unresponsive to stimuli, loss of consciousness, depressed level of consciousness, convulsions, syncope, psychomotor hyperactivity, balance disorder, coordination abnormal, dizziness postural, disturbance in attention, dysarthria, dysgeusia, hypoesthesia, paraesthesia, fall, procedural pain.

MARKETED BY:

TORRENT
PHARMA

Torrent Pharmaceuticals Limited.

IN/ ZISPER®IR 1 mg, 2 mg, 3 mg and 4 mg /MAR 2026/01/ABPI

(Additional information is available on request)